Harbour BioMed announced the results of phase Ib clinical trial of porustobart, in combination of toripalimab in patients with hepatocellular carcinoma were released at the American Society of Clinical Oncology Annual Meeting 2023.
Harbour BioMed announced the results of phase Ib clinical trial of porustobart, in combination of toripalimab in patients with hepatocellular carcinoma were released at the American Society of Clinical Oncology Annual Meeting 2023.